Evidence map›Paper›PMID 28728165›Full record

ArticleBritish journal of cancer2017

Active multiple myeloma suppresses and typically eliminates coexisting MGUS.

John P Campbell, Jennifer L J Heaney, Sankalp Pandya, Zaheer Afzal, Martin Kaiser, Roger Owen, J Anthony Child, Walter Gregory, Gareth J Morgan, Graham H Jackson and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

John P CampbellInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
Jennifer L J HeaneyInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
Sankalp PandyaInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
Zaheer AfzalInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
Martin KaiserInstitute of Cancer Research, London SM2 5NG, UK.
Roger OwenSt James's University Hospital, Leeds LS9 7TF, UK.
J Anthony ChildSt James's University Hospital, Leeds LS9 7TF, UK.
Walter GregoryClinical Trials Research Unit, University of Leeds, Leeds LS2 9NL, UK.
Gareth J MorganThe Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Graham H JacksonUniversity of Newcastle, Newcastle upon Tyne NE1 7RU, UK.
Chris M BunceSchool of Biosciences, University of Birmingham, Birmingham B15 2TT, UK.
Mark T DraysonInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.

Funding

Medical Research Council G0100132
6 · The paper itself

Abstract

backgroundMyeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.

methodsIn the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.

resultsCompared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.

conclusionMyeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.

Indexed as

AdultAgedAged, 80 and overAnalysis of VarianceAntibodies, MonoclonalCell SizeDisease ProgressionHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MMiddle AgedMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaPrecancerous ConditionsPrevalenceAntibodies, MonoclonalImmunoglobulin AImmunoglobulin GImmunoglobulin M

Identifiers

PMID28728165
PMCPMC5589985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.